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In patients with cancer-associated venous thromboembolism, knowledgeof the estimated rate of recurrent events is important for clinical decision-making regarding anticoagulant therapy. The Ottawa score is a clinical
prediction rule designed for this purpose, stratifying patients according to
their risk of recurrent venous thromboembolism during the first six months
of anticoagulation. We conducted a systematic review and meta-analysis of
studies validating either the Ottawa score in its original or modified versions.
Two investigators independently reviewed the relevant articles published
from 1st June 2012 to 15th December 2018 and indexed in MEDLINE and
EMBASE. Nine eligible studies were identified; these included a total of
14,963 patients. The original score classified 49.3% of the patients as high-
risk, with a sensitivity of 0.7 [95% confidence interval (CI): 0.6-0.8], a 6-
month pooled rate of recurrent venous thromboembolism of 18.6%
(95%CI: 13.9-23.9). In the low-risk group, the recurrence rate was 7.4%
(95%CI: 3.4-12.5). The modified score classified 19.8% of the patients as
low-risk, with a sensitivity of 0.9 (95%CI:  0.4-1.0) and a 6-month pooled
rate of recurrent venous thromboembolism of 2.2% (95%CI: 1.6-2.9). In the
high-risk group, recurrence rate was 10.2% (95%CI:  6.4-14.6). Limitations
of our analysis included type and dosing of anticoagulant therapy. We con-
clude that new therapeutic strategies are needed in patients at high risk for
recurrent cancer-associated venous thromboembolism. Low-risk patients, as
per the modified score, could be good candidates for oral anticoagulation.
(This systematic review was registered with the International Prospective
Registry of Systematic Reviews as: PROSPERO CRD42018099506). 
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ABSTRACT
Introduction
Cancer is one of the most frequent risk factors for venous thromboembolism
(VTE) and for VTE recurrence while on anticoagulation.1,2 In patients with VTE and
cancer, the rate of recurrent VTE despite anticoagulation can reach up to 20% after
six months of therapy, but this rate highly depends on several patient and cancer
characteristics.3 For example, age, residual thrombosis, previous history of VTE, sur-
gical procedures within three months prior to VTE, cancer stage, and the site and
histology of the malignancy all impact the 6-month rate of
recurrent VTE.4-8 The anticoagulant therapy used [e.g. vita-
min K antagonist, direct oral anticoagulants or low molec-
ular weight heparin (LMWH)] may also influence the rate
of recurrent VTE. Reliable identification of which patients
are at high or low risk of recurrent VTE recurrence must
be performed to aid clinical decision-making regarding the
type of anticoagulant therapy.
For this, the Ottawa score was designed  to stratify the
risk of recurrent VTE during the first six months of antico-
agulant therapy in patients with cancer-associated VTE.9
Two scores were derived. The original score (female sex,
lung cancer, and prior history of VTE each give 1 point;
breast cancer gives a negative point; cancer stage I gives 2
negative points) dichotomizes patients into low (score ≤ 0)
or high (score ≥ 1) risk for VTE recurrence. The modified
score (female sex, lung cancer, and prior history of VTE
each give 1 point; breast cancer and cancer stage I + II each
give a negative point) classifies patients into low (score
≤−1), intermediate (score = 0), and high (score ≥ 1) risk for
VTE recurrence. However, the accuracy of these two clin-
ical models remains to determine. 
To determine if the Ottawa risk score (i.e. original and
modified) can reliably identify the risk of recurrent VTE
during the first six months of anticoagulation in cancer
patients with VTE, we conducted a systematic review and
meta-analysis of the literature. 
Methods  
The guidelines of the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) Statement were followed.
The systematic review was registered with the International
Prospective Registry of Systematic Reviews (PROSPERO
CRD42018099506).
Search strategy and study selection 
We systematically searched Medline and Embase, using the
following key words: recurrent venous thromboembolism AND
cancer AND (decision tree OR clinical prediction rule OR clinical
prediction score OR clinical decision rule OR management stud-
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Figure 1. Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) Statement  flow dia-
gram. 
ies OR outcome studies OR decision support techniques),
(venous thromboembolism recurrence) AND cancer AND (deci-
sion tree OR clinical prediction rule OR clinical prediction score
OR clinical decision rule OR management studies OR outcome
studies OR decision support techniques). The search was limited
to English and French language studies. Literature search was
restricted to 1st  June 2012 to 15th December 2018, since the
Ottawa score was published online in June 2012. To ensure a
comprehensive literature search, we examined reference lists
from retrieved articles and reference literature (guidelines and
systematic reviews), and contacted experts in the management
of cancer-associated VTE for possible missing studies. Eligible
studies were those validating either the original or the modified
Ottawa scores. If key data were missing, study authors were
contacted to request the relevant data. Two investigators inde-
pendently evaluated studies for possible inclusion (AD and SM).
They  independently assessed study quality and extracted the
data on study design and patient characteristics. Disagreements
about extracted data were resolved by consensus or by discus-
sion with a third reviewer (MC).
Quality assessment and data extraction
Methodological quality of included studies was assessed inde-
pendently by two observers (AD and SM) using the Hayden qual-
ity assessment tool specifically developed for systematic reviews
of prognosis studies.10 This tool assesses six potential biases. 1) Is
the population of interest represented in the study sample? 2) Are
there cases of Loss to Follow Up that are not associated with key
characteristics? 3) Is there adequate measurement of the prognos-
tic factors? 4) Is there adequate measurement of the outcome of
interest? 5) Are important confounders accounted for? 6) Has the
appropriate statistical analysis been conducted? Regarding the
study population criterion, we considered as representative
cohorts those that included consecutive patients with document-
ed cancer-associated VTE with at least six months of follow up. 
We collected the following data for each study: year of publica-
tion, score evaluated (original or modified), data collection meth-
ods (retrospective or prospective), setting (outpatient, inpatient or
both), geographic location, demographics (mean age, percentage
of women), follow-up duration, overall prevalence of recurrent
VTE, distribution of patients in each pre-test probability group,
and prevalence of VTE in each pre-test probability group.
The primary outcome of the study was the pooled prevalence
of recurrent VTE in each risk group after six months of anticoagu-
lation.
Data analysis 
Publication bias was explored by funnel plots and Egger’s test.
We determined the 95% confidence intervals (CI) of the preva-
lence of recurrent VTE in the various clinical probability categories
using the exact method. The prevalence of VTE in each level of
clinical probability was separately assessed using the method of
the inverse variance on the arcsine-transformed proportions.
Heterogeneity was tested with the Cochran Q statistic and also
quantified by the indicator I2 (ranging from 0% for perfect homo-
geneity to 100% for extreme heterogeneity). In case of hetero-
geneity (Cochran Q test with a P-value < 0.10 or I2 > 50%), a ran-
dom effects model was used.11
All analyses were performed using STATA14 (StataCorp,
College Station, TX, USA) using the metaprop command.12
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Table 1. Characteristics of the studies.
Studies                         Score    Characteristics*   Setting       Inclusion        N       Age   Female    Lung       Breast  Metastases  History         VTE 
                                                                                                   period                  (mean)    sex      cancer      cancer                       of VTE     recurrence
                                                                                                                                                                                                                               rate
Louzada                           Original               R, D         Single-center   2002-2004      543**      63         303            96                 85                321               46                  55 
derivation                      Modified                                                            2007-2008                                (55.8%)   (17.7%)      (15.6%)      (66.2%)      (8.5%)        (10.1%)
(2012)9                                     
Louzada                          Modified               P, V            Multicenter     1995-1999        819         -          427           106               139               526               96                  86
validation (2012)9                                                                                      1999-2001                               (52.1%)  (12.9%)      (17.0%)      (71.8%)       (11.7)         (10.5%)
Louzada                           Original               R, V           Multicenter     2006-2010        353         64         204            62                 39               230               77                 44
validation (2012)14                                                                                     2009-2011                                (57.7%)   (17.5%)      (11.0%)   (75.7%)*** (21.8%)      (12.5%)
                                                                                                                                                 
Den Exter                      Modified               P, V            Multicenter     2001-2010        419         60         197            64                 33                252               39                  35
(2013)17                                                                                                                                                          (47.0%)   (15.3%)       (7.9%)       (71.2%)      (9.3%)         (8.4%)
                                                                                                                               
Ahn (2013)19                    Original               R, V          Single-center   2007-2010        546         58         294            94                 36                406               26                  99
                                                                                                                                                                        (53.8%)   (17.2%)       (6.6%)       (74.4%)      (4.8%)        (18.1%)
Astruc (2016)13              Modified               P, V          Single-center   2000-2010        156         69          70             23                 17                 62                36                  14
                                                                                                                                                                        (44.8%)   (14.7%)      (10.9%)      (39.8%)     (23.1%)       (11.9%)
Alatri (2017)16                Modified               P, V            Multicenter     2001-2016      11123       67        5145         1691             1407             6127           1347               477
                                                                                                                                                                        (46.2%)   (15.2%)      (12.6%)      (55.1%)     (12.1%)        (4.3%)
Khorana (2017)18           Modified               P, V            Multicenter     2010-2013        900         59         537           104                84                492               57                  76
                                                                                                                                                                        (59.6%)   (11.5%)       (9.3%)       (54.7%)      (6.3%)         (8.4%)
van Es (2018)15               Original               P, V            Multicenter     2012-2014        117         63          59             26                 10                 89                 0                   11
                                                                                                                                                                        (50.4%)   (22.2%)       (8.5%)      ((76.0%)                           (9.4%)
                                                                            
*P: prospective; R: retrospective; V: validation; D: derivation; **Missing data for 13 patients; *** TNM>1; N: number; VTE: venous thromboembolism;
***Tumor node metastasis>1. 
Results  
Study selection
The literature search identified 329 article records of
which 229 were assessed for eligibility (Figure 1). Nine
studies reporting data on 14,963 patients were eligible and
were included in the analyses.9,13-19
Study characteristics
Study characteristics are depicted in Table 1. Of the
reported studies, six were prospective, six were multicen-
ter, and four used the original score. In total, seven studies
were validation studies of the Ottawa score. Mean age of
the patients was 58-69 years; female gender accounted for
45-59% of the patients.
Risk of bias within studies
Risk of bias is summarized in Online Supplementary
Appendix 1. For six studies, at least four out of six potential
bias areas were judged satisfied.9,14-16,18 Confounding meas-
urement was not accounted for in all studies, and attrition
was accounted for in only one study.18 A significant publi-
cation bias between the studies was observed (P=0.001)
(Online Supplementary Appendix 2A). This bias was only
observed in studies reporting on the modified score
(Online Supplementary Appendix 2B and C).
Synthesis of results
All nine identified studies were included in the meta-
analysis. Data were extracted from original publications
for six studies9,13-15,19 or, after that, additional data were pro-
vided by corresponding authors.16-18 The overall 6-month
rate of recurrent VTE varied from 4.3% to 18.1% in the
different studies; the overall 6-month pooled rate was
9.8% (95%CI: 6.4-13.8; I2=96%). 
The original Ottawa score was derived in one and vali-
dated in three studies.9,14,15,19 The total number of patients
included in these studies was 1,558 with an overall pooled
6-month rate of recurrent VTE of 12.7% (95%CI: 8.9-17.2,
I2=81%). Overall, 763 (49.3%) patients were classified in
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Figure 2. Pooled recurrence rates of
venous thromboembolism for the
original Ottawa score. (A) Pooled
recurrence rates of venous throm-
boembolism for the original Ottawa
score in high-risk patients. (B)
Pooled recurrence rates of venous
thromboembolism for the original
Ottawa score in low-risk patients
A
B
the high-risk category with a pooled 6-month recurrence
rate of VTE of 18.6% (95%CI: 13.9-23.9) (I2=64%, P=0.04)
(Figure 2A). Of the remaining 795 patients (classified in
the low-risk category), the pooled 6-month rate of recur-
rent VTE was 7.4% (95%CI: 3.4-12.5) (I2=81%, P<0.01)
(Figure 2B). The estimated pooled sensitivity, specificity,
and Area Under the Receiver Operating Characteristic
curve (AUROC) of the original score to identify high-risk
patients were 0.7 (95%CI: 0.6-0.8), 0.5 (95%CI: 0.5-0.6),
and 0.7 (0.6-0.8), respectively. 
The modified score was derived in one and validated in
four studies.9,13,16-18 The pooled 6-month rate of recurrent
VTE in the 13,419 studied patients was 7.85% (95%CI:
4.79-11.57) (I2=95%, P<0.01). The modified score classi-
fied 5,307 (39.5%) patients in the high-risk category, in
which the pooled 6-month rate of recurrent VTE was
10.2% (95%CI: 6.4-14.6) (I2=89%, P<0.01) (Figure 3A). A
total of 2,653 patients (19.8%) were classified in the low-
risk category with a pooled 6-month rate of recurrent VTE
of 2.2% (95%CI: 1.6-2.9) (I2=0%, P=0.51) (Figure 3B). For
the remaining 5,459 patients in the intermediate-risk cate-
gory, the pooled 6-month rate of recurrent VTE was 7.1%
(3.8-11.3) (I2=90%, P<0.01) (Figure 3C).
The estimated pooled sensitivity, specificity, and
AUROC of the modified score to identify high-risk
patients were 0.5 (95%CI: 0.5-0.6), 0.6 (95%CI: 0.5-0.7),
and 0.5 (95%CI: 0.5-0.6), respectively. For the identifica-
tion of low-risk patients these characteristics were 0.9
(95%CI: 0.8-1.0), 0.2 (95%CI: 0.1-0.2), and 0.5 (95%CI:
0.5-0.7), respectively.
Pooled incidences of recurrent VTE for each point cate-
gory using the original and the modified Ottawa scores
are reported in Online Supplementary Appendix 3. The rates
of recurrent VTE ranged from 0 to 37.1% (95%CI: 12.7-
64.7) with a dose-effect association in studies applying the
original score and ranged from 0 to 9.1% (95%CI: 0.2-
24.7) in studies applying the modified score with a step-
wise association.
Discussion  
This systematic review and meta-analysis of nine studies
involving a total of 14,963 patients with cancer-associated
VTE, confirms that the Ottawa score is an accurate tool to
stratify the risk for recurrent VTE within the first six
months of anticoagulation. The original Ottawa score can
reliably identify patients with cancer-associated VTE at
high risk of recurrent events, whereas the modified score is
best suitable for identifying cancer patients with low risk
of VTE recurrence. The original score classified 49.3% of
the patients into the high-risk group with a sensitivity of
71% and the modified score classified 19.8% of the
patients into the low-risk group with a sensitivity of 92%. 
The Ottawa scores (original and modified) are the only
tools available to stratify the risk for recurrence of cancer-
associated VTE. The scores can help identify patients with
a rate of recurrent VTE  >10%. This has been suggested as
clinically relevant and considered as a “high-risk”
category.20 The Ottawa scores have better accuracy than
the reported sensitivity, specificity or AUROC values,
which were calculated based on crude rates of recurrent
A. Delluc et al.
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Figure 3. Pooled recurrence rates of venous thromboembolism for the
modified Ottawa score. (A) Pooled recurrence rates of venous throm-
boembolism for the modified Ottawa score in high-risk patients (B)
Pooled recurrence rates of venous thromboembolism for the modified
Ottawa score in intermediate-risk patients. (C) Pooled recurrence rates




VTE as opposed to correct classification. If patients were
classified a priori by risk categories (i.e. “high-risk”, “low-
risk”) similar to how a diagnostic test would be reported
as “disease”, or “no disease”, it is very likely that estimates
of intrinsic properties of the Ottawa score would improve.
Furthermore, when considering our meta-analysis across
each sum of points, we could demonstrate a dose-effect
relationship, either continuous (original score) or stepwise
(modified score), which confirmed the accuracy of the risk
classification of the Ottawa scores. 
The accuracy of the modified Ottawa score to identify
patients at low risk for VTE recurrence has a potential
major therapeutic impact that should be considered for
implementation into daily practice. The low 2.2% risk of
recurrent VTE in this patient population closely mirrors
the recurrent risk of the general VTE population21,22 (refer
to DOAC trials). In this setting, the potential advantages
of LMWH over oral anticoagulation are clearly counterbal-
anced by their cost, their negative impact on quality of
life, and the expected low absolute risk reduction of recur-
rent VTE (<2% based on a 50% relative risk reduction).23,24
The use of oral anticoagulants in low-risk patients is,
therefore, clinically relevant and could be systematically
considered as first line in this specific risk group. In con-
trast, 49.3% of the patients were classified in the high-risk
group by the original Ottawa score. The unacceptable
18.6% estimated rate of recurrent VTE, despite anticoagu-
lant treatment, in this group warrants the urgent develop-
ment of new therapeutic strategies.
Strengths of our study include its comprehensiveness
and the large number of patients included; however, we
acknowledge several limitations. First, there was a signifi-
cant heterogeneity between studies and some publication
bias, particularly in validation studies of the modified
score. Nevertheless, most of the studies were of good
quality. A major source of heterogeneity was the large dif-
ference in incidence rates of recurrent VTE across the stud-
ies. Most datasets were old and included patients receiv-
ing out-dated cancer therapies. These therapies may have
exposed patients to higher risk of recurrent VTE, leading
to an overestimation of the current risk. However, the
most recent study using the original or modified scores
reported an overall recurrence rate of VTE of 9.4 and
8.4%, respectively, which remains high and clinically rel-
evant.15,18 Specific center-related factors that could also
potentially affect recurrence-rate of VTE include academic
centers, age of included patients and their socio-economic
level, number of comorbidities, higher stage disease, his-
tory of VTE, and ethnicity. The second limitation of our
study was we were unable to account for the type of anti-
coagulation used. None of the studied patients were treat-
ed with a direct oral anticoagulant. Data on exposure to
LMWH or vitamin K antagonist was not available in any
of  the identified studies. In the derivation and in some of
the validation studies, the type of anticoagulation was not
a significant predictor for VTE recurrence. However,
among all randomized trials, only one showed the superi-
ority of LMWH over vitamin K antagonists to treat cancer-
associated VTE.25 Third, we could not assess the impor-
tance of other risk factors for VTE recurrence (e.g. inter-
ruption of anticoagulants for an invasive procedure, age,
etc.) during follow up. However, the Ottawa scores were
derived without accounting for these confounders and
appeared to accurately classify patients. Fourth, patients
classified by the original score in the low-risk category had
an estimated rate of VTE recurrence of 7.4%, which can-
not be considered as low. However, when the score was
initially derived, the objective was to identify patients
with an a priori risk for VTE recurrence during anticoagu-
lation of <7%. In that instance, our data confirm the accu-
racy of the original score.
In conclusion, the Ottawa score, either in its original or
modified form, is a useful tool to stratify the 6-month risk
for VTE recurrence during anticoagulation in patients with
cancer-associated VTE. Specifically, the original and mod-
ified Ottawa score can accurately identify patients with
cancer-associated VTE at high and low risk of recurrent
events, respectively. There is an urgent need for the devel-
opment of new therapeutic strategies to prevent recurrent
VTE in high-risk patients. The original score is an accurate
tool to define inclusion criteria of future studies.  
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